CLOs on the Move

MedPro Services

www.medproservices.net

 
MedPro Services is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Infusion Systems

Infusion Systems is a Valencia, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

CareFinders Total Care

Care Finders Total Care provides the highest level of home care and personalized service to patients of all ages including children, adults and the elderly. Care Finders Total Care provides reliable Certified Home Health Aides who will make sure that while they provide the care you need, your independence, dignity and religious customs are maintained, regardless of your disability or illness.

Geary Community Hospital

Geary Community Hospital is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Junction City, KS. To find more information about Geary Community Hospital, please visit www.gchks.org

Nivano Physicians

Nivano Physicians is an Independent Physician Association (IPA) that operates within Sacramento and surrounding counties. They are committed to advocating for the Medi-Cal community and ensuring that managed healthcare is manageable.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.